Ampio Pharmaceuticals Inc. (AMEX:AMPE) went down by -8.02% from its latest closing price compared to the recent 1-year high of $2.59. The company’s stock price has collected -9.09% of loss in the last five trading sessions. Press Release reported on 01/06/22 that Ampio Pharmaceuticals Presents Corporate Overview at H.C. Wainwright Bioconnect Conference
Is It Worth Investing in Ampio Pharmaceuticals Inc. (AMEX :AMPE) Right Now?
Plus, the 36-month beta value for AMPE is at 1.51. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Ampio Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
AMPE currently public float of 188.18M and currently shorts hold a 10.44% ratio of that float. Today, the average trading volume of AMPE was 1.68M shares.
AMPE’s Market Performance
AMPE stocks went down by -9.09% for the week, with a monthly drop of -23.71% and a quarterly performance of -70.06%, while its annual performance rate touched -65.03%. The volatility ratio for the week stands at 8.48% while the volatility levels for the past 30 days are set at 10.49% for Ampio Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -15.94% for AMPE stocks with a simple moving average of -66.49% for the last 200 days.
Analysts’ Opinion of AMPE
Many brokerage firms have already submitted their reports for AMPE stocks, with ROTH Capital repeating the rating for AMPE by listing it as a “Buy.” The predicted price for AMPE in the upcoming period, according to ROTH Capital is $4 based on the research report published on December 19th of the previous year 2019.
Aegis Capital, on the other hand, stated in their research note that they expect to see AMPE reach a price target of $16, previously predicting the price at $15. The rating they have provided for AMPE stocks is “Buy” according to the report published on March 17th, 2014.
Aegis Capital gave a rating of “Buy” to AMPE, setting the target price at $11 in the report published on September 25th of the previous year.
AMPE Trading at -49.33% from the 50-Day Moving Average
After a stumble in the market that brought AMPE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.69% of loss for the given period.
Volatility was left at 10.49%, however, over the last 30 days, the volatility rate increased by 8.48%, as shares sank -13.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -67.74% lower at present.
During the last 5 trading sessions, AMPE fell by -9.09%, which changed the moving average for the period of 200-days by -69.51% in comparison to the 20-day moving average, which settled at $0.5908. In addition, Ampio Pharmaceuticals Inc. saw -12.28% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at AMPE starting from STOKELY DAN, who sale 22,500 shares at the price of $1.79 back on Jun 25. After this action, STOKELY DAN now owns 28,315 shares of Ampio Pharmaceuticals Inc., valued at $40,275 using the latest closing price.
Cherevka Holli, the CHIEF OPERATING OFFICER of Ampio Pharmaceuticals Inc., sale 2,603 shares at $2.00 during a trade that took place back on May 21, which means that Cherevka Holli is holding 0 shares at $5,206 based on the most recent closing price.
Stock Fundamentals for AMPE
Equity return is now at value -86.00, with -66.00 for asset returns.